Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

FDA Concludes Safety Review Of Novartis MS Drug Gilenya

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/14/2012 | 06:55pm CEST

--FDA concludes safety review of MS drug Gilenya

--FDA advises against use in certain heart and stroke patients

--FDA says no clear link between Gilenya and cardiovascular deaths

(Updates with additional background on EMA review starting in seventh paragraph and information on experimental Biogen Idec MS drug.)

 
   By Jennifer Corbett Dooren 
   Of  
 

The U.S. Food and Drug Administration Monday said Novartis AG's (NVS, NOVN.VX) multiple-sclerosis drug Gilenya shouldn't be used in patients with a recent history of stroke or some types of heart problems, concluding a safety review of the drug.

The safety review was prompted by a report last November of a 59-year-old patient dying in the U.S. less than 24 hours after taking the first dose of the drug.

The agency said it continues to recommend that doctors closely monitor the hearts of patients after they have been given the first dose of the drug because the product can lower a person's heart rate temporarily.

As for the patient's death, the FDA said an exact cause of death couldn't be identified. The FDA said the patient had extensive brainstem MS lesions, which also have been associated with sudden death. The FDA also said it looked at other deaths that appeared to be from cardiovascular causes in patients who had been taking Gilenya and concluded that the drug's "contribution to the death was unclear."

The FDA said the drug shouldn't be used in patients who have had a stroke or heart trouble within the past six months. The agency also said the drug shouldn't be used in patients taking some kinds of antiarrhythmic heart medicines.

Europe's drug regulator, the European Medicines Agency, last month requested stronger safety warnings for Gilenya after the agency concluded its review of the drug.

Gilenya is currently the only oral MS drug on the market but its sales prospects have been clouded by recent safety concerns. It was approved in the U.S. in 2010 and has been available in Europe since 2011.

The product is designed to treat patients with the relapsing form of MS, which is a progressive disease that involves damage to the nerves controlling muscles and vision.

The FDA is currently reviewing another oral MS drug from Biogen Idec Inc. (BIIB) called BG-12 that is designed to work through a different mechanism than Gilenya. Biogen Idec last week announced that the FDA accepted BG-12's new drug application for a standard 10-month review, which sets an agency decision deadline of about Dec. 28.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
10/19 NOVARTIS : Recent Findings from Novartis Provide New Insights into Glucosyltrans..
10/19 GILEAD SCIENCES : 2nd gene therapy for blood cancer approved
10/19 NOVARTIS : Drug Revolade(R) Shows Long-Term Disease Control for Chronic/Persiste..
10/19 NOVARTIS : sheds generics plant and 450 jobs amid pricing pressure
10/19 NOVARTIS : FDA OKs 2nd gene therapy for blood cancer; 1st for adults
10/18 NOVARTIS : 450 jobs to go as pricing pressures push Novartis to close CO generic..
10/18 NOVARTIS : drug Revolade® shows long-term disease control for chronic/persistent..
10/13 NOVARTIS : Alcon Laboratories, Inc. Constellation LXT Vitrectomy/ Vitreoretinal ..
10/13 NOVARTIS : 65-- Alcon Laboratories, Inc. Constellation LXT Vitrectomy/ Vitreoret..
10/13 NOVARTIS AG (ADR)(NYSE : NVS) Says It Will Not Sell Its Stake In Roche
More news
News from SeekingAlpha
10/20 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update
10/19 BIOTECH FORUM DAILY DIGEST : Spotlighting Ignyta's Big Recent Rally
10/19 What 'Yes' For Its CAR-T Therapy May Mean For Gilead
10/19 YOUR DAILY PHARMA SCOOP : Gilead's Brave New World, AZN's Lynparza SNDA, RXDX En..
10/19 FDA Approval Of Gilead CAR-T Therapy Will Move The Needle
Financials ($)
Sales 2017 48 864 M
EBIT 2017 11 614 M
Net income 2017 7 295 M
Debt 2017 17 700 M
Yield 2017 3,32%
P/E ratio 2017 24,53
P/E ratio 2018 21,59
EV / Sales 2017 5,00x
EV / Sales 2018 4,78x
Capitalization 226 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 87,4 $
Spread / Average Target 1,9%
EPS Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS13.50%226 404
JOHNSON & JOHNSON23.29%377 585
ROCHE HOLDING LTD.5.55%215 760
PFIZER11.58%213 372
MERCK AND COMPANY7.88%173 214
AMGEN27.41%135 924